Intelligence / Healthtech / New Clinical Trials / Wockhardt
Clinicaltrial registered21 Oct 2026
Wockhardt
21 Oct 2026: Trial registered · Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 21 Oct 2026
- Title
- Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
- Conditions
- Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Bosnia and Herzegovina, Bulgaria, Croatia, France, Georgia, Greece, India, Italy, Lithuania, Moldova, North Macedonia, Poland, Romania, Serbia
- Country
- Bosnia and Herzegovina
- Reference
- NCT07885891
- Location
- Bosnia and Herzegovina, Bulgaria, Croatia
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Wockhardt
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.